Original Article

You have full text access to this OnlineOpen article

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma†

A randomized, double-blind, multicenter, comparative trial

  1. Lee S. Rosen M.D.1,‡,*,
  2. David Gordon M.D.2,
  3. Mary Kaminski M.D.3,
  4. Anthony Howell B.Sc., M.Sc., M.B., B.S.4,
  5. Andrew Belch M.D.5,
  6. John Mackey M.D.5,
  7. Justus Apffelstaedt M.D.6,
  8. Mohamad A. Hussein M.D.7,§,
  9. Robert E. Coleman M.D.8,¶,
  10. Dirk J. Reitsma M.D.9,‖,
  11. Bee-Lian Chen Ph.D.9,‖,
  12. John J. Seaman Pharm.D.9,‖

Article first published online: 29 AUG 2003

DOI: 10.1002/cncr.11701

Issue

Cancer

Cancer

Volume 98, Issue 8, pages 1735–1744, 15 October 2003

Additional Information

How to Cite

Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., Chen, B.-L. and Seaman, J. J. (2003), Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 98: 1735–1744. doi: 10.1002/cncr.11701

Author Information

  1. 1

    Developmental Therapeutics, Cancer Institute Medical Group, Santa Monica, California

  2. 2

    Medical Oncology/Hematology, US Oncology, San Antonio, Texas

  3. 3

    American Medical Research Institute, Kennesaw, Georgia

  4. 4

    CRC Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester, United Kingdom

  5. 5

    Department of Medicine, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

  6. 6

    Mamma Clinic, Tygerberg Hospital, Cape Town, South Africa

  7. 7

    Myeloma Research Program, Cleveland Clinic, Cleveland, Ohio

  8. 8

    Academic Unit of Oncology, Weston Park Hospital, Cancer Research Centre, Sheffield, United Kingdom

  9. 9

    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

  1. ‡

    Fax: (310) 998-3965

  2. §

    Dr. Hussein has received a research grant from Novartis

  3. Dr. Coleman has received honoraria from Novartis

  4. ‖

    Dr. Seaman, Dr. Chen, and Dr. Reitsma are employed by Novartis Pharmaceuticals and may own stock in the company

*Director of Developmental Therapeutics, Cancer Institute Medical Group, 2001 Santa Monica Boulevard, Suite 560W, Santa Monica, CA 90095

  1. †

    Performed on behalf of the Zoledronic Acid Breast Cancer and Multiple Myeloma Study Group

Publication History

  1. Issue published online: 3 OCT 2003
  2. Article first published online: 29 AUG 2003
  3. Manuscript Accepted: 14 JUL 2003
  4. Manuscript Revised: 23 JUN 2003
  5. Manuscript Received: 5 MAR 2003

Funded by

  • Novartis Pharmaceuticals Corporation (East Hanover, New Jersey)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (151K)

REFERENCES

  • 1
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49: 33–64.
    Direct Link:
  • 2
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 15–36.
    Direct Link:
  • 3
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80 (8 Suppl): 1588–1594.
    Direct Link:
  • 4
    Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975; 50: 29–40.
  • 5
    Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997; 69: 1–18.
  • 6
    Harrington KD. Orthopedic surgical management of skeletal complications of malignancy. Cancer. 1997; 80: 1614–1627.
    Direct Link:
  • 7
    Manglani HH, Marco RA, Picciolo A, Healey JH. Orthopedic emergencies in cancer patients. Semin Oncol. 2000; 27: 299–310.
  • 8
    Eke N. Symptomatic spinal cord involvement in prostate cancer. Cent Afr J Med. 2001; 47: 49–53.
  • 9
    Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist. 2002; 7 (Suppl 1): 20–29.
  • 10
    RiesLAG, EisnerMP, KosaryCL, et al., editors. SEER cancer statistics review, 1973–1999. Bethesda: National Cancer Institute, 2001.
  • 11
    Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 2000; 89: 363–368.
    Direct Link:
  • 12
    Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88: 1082–1090.
    Direct Link:
  • 13
    Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16: 2038–2044.
  • 14
    Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999; 17: 846–854.
  • 15
    Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16: 593–602.
  • 16
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996; 334: 488–493.
  • 17
    Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994; 9: 745–751.
    Direct Link:
  • 18
    Maxwell C, Swift R, Goode M, Doane L, Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurse. 2003; 7: 403–410.
  • 19
    Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol. 2001; 28: 17–24.
  • 20
    Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21: 3150–3157.
  • 21
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458–1468.
  • 22
    Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 295a.
  • 23
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377–387.
  • 24
    Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19: 558–567.
  • 25
    Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982; 10: 1100–1120.
  • 26
    George ED, Sadovsky R. Multiple myeloma: recognition and management. Am Fam Physician. 1999; 59: 1885–1894.
  • 27
    Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer. 2000; 88 (12 Suppl): 3022–3032.
    Direct Link:
  • 28
    Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002; 25 (Suppl 1): S10–S18.
  • 29
    DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001; 9: 545–551.
View Full Article (HTML) Get PDF (151K)